Dotatate gallium (Ga-68) is a somatostatin-2 receptor analog which is radiolabeled with gallium 68 as a positron-emitting radioisotope. Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is... Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016.
- Mechanism
- Curator reviewed · 1 reference
The somatostatin receptor-based imaging is the preferred choice in the diagnostic and management of neuroendocrine tumors. The basis for the mechanism of dotatate gallium 68 is the binding of a ligand analog that is radiolabeled, in this case thye preferred binding site is the receptors of the subtype 2. The malignant cells are reported to overexpress the somatostatin subtype 2 receptor. Dotatate gallium 68 is a β+ emiting radionuclide with an emission yield that can be detected by the positron emission tomography and thus the seletive binding to the overexpressed somatostatin receptor will be detected.
- Primary indication
- Dotatate gallium 68 is one of the most prominent radiopharmaceuticals used in imaging with positron emission tomography.Curator reviewed · 1 structured indication
- Formula / weight
- C65H87GaN14O19S2 · 1500.54 g/mol (avg)
- Also known as
- (68)Ga-DOTA-TATE · (68Ga)Gallium dotatate · [68Ga] DOTATATE · 68Ga DOTA TATE · 68Ga-DOTA-TATE
Resolves to
XBJPSVQFCQFGDC-WSCOIBMGSA-KSMILES[68Ga+3].C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(O)=OWhat you can answer from here — as of March 24, 2026
Which drugs share a target with Dotatate gallium Ga-68, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account